Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-RT regimen in unresectable locally advanced NSCLC: The ETOP NICOLAS phase II trial.
暂无分享，去创建一个
U. Dafni | D. Ruysscher | R. Stahel | S. Peters | E. Felip | C. Belka | J. Vansteenkiste | R. Huber | M. Guckenberger | N. Andratschke | H. Roschitzki-Voser | M. Lambrecht | A. Irigoyen | A. Piguet | A. Gasca‐Ruchti | M. Kassapian | A. Becker | A. Marti | Ernest Nadal-Alforja | M. Kassapian